Steve (thank you Phoebe), yes, we
met several years ago and I now happen to be involved with an AI VC group
that is comprised of mostly MIT people out of Denver. We're going to
be meeting with some people in Utah on this Wednesday.
If you would have Neville and me at your 7 am Bagel mee
ting, the
AI topics that Neville Teagarden (his bio attache
d) would cover, include his perspective on where AI, in particular what he
calls applied AI, is in its development and application right now.
I think what would be of
high interest is one of the companies our company has invested in who has
worked with Ernst & Young to determine a GAAP
Compliant
approach to assigning a balance sheet value to data, particularly customer
and other data that a company may have that heretofore has not been an ass
et that can be placed on a company balance sheet.
The publicity and practice of this is just starting, and I c
an provide a link to a legal briefing on it from Ropes & Gray, the top
tier law firm.
The second intere
sting thing is the way this AI company has been collecting patient data for
what had become one of the more valuable data sets that AI companies will
seek, particularly companies that want to potentially do virtual FDA trials
with patient data that has been sanitized, that is, with no identifiers to
people, but which is cross-tabbed with genomics. AI will make thia d
ata enormously valuable and many people think this will be a huge move forw
ard in drug discovery and drug treatments for things like cancer. Thi
s particular company has already amassed over 27 million patient records ar
ound the world, diversified by gender and race, and the company, led by ano
ther MIT AI grad, started this 3 years ago before much of this was on the r
adar screen at all.
Neville was
a student back when at MIT with Marvin Minsky as his prof and mentor.
; Prof. Minsky is considered to be the father of AI. (See Marvin Minsk
y, Pioneer in Artificial Intelligence,
https://nyti.ms/1lM1rkl). Neville, therefore,
has much more than a Johnny-come-lately view about artificial intelligence.
The idea is to give your folks som
e insight as to what's going on in AI and some new things that probably nob
ody is aware of. We totally understand this is not about doing an investmen
t pitch so don't worry about that.
I'll be there, I can also throw in a few words, anecdotes about how I just
successfully took a very interesting scientific compound company public on
NASDAQ a few weeks ago through a SPAC. I could tell you a lot about t
he current state of the SEC and what I had to deal with as Chair of the Aud
it committee of a public company under the current SEC Chair Genslar!
We will be staying up in Park City Wedne
sday night so Thursday am early would work perfectly if you would tell wher
e to be at what time
Many thanks in
advance,
Gene Podsiadlo
Cell 801 557 3964
.
Gene Podsiadlo
CLEARBROOK
Cell: 801 557 3964
Mendon, Utah
Meet Gene. He would be a good speaker for your LSDM group esp
ecially relating to AI investing most recently. He is a former Warburg Pinc
us Partner and Wasatch board member. I will let him propose a speaking topi
c etc.., But he is involved in many things.
I don’t know what your speaker docket looks like but he could d
o something as soon as Thursday.
Phoeb
e